United Kingdom

People: Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

13 Sep 2019
Change (% chg)

$-0.32 (-1.41%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bloom, Floyd 

Dr. Floyd E. Bloom M.D. is Independent Director of the Company. Dr. Bloom was a founder of Alkermes, Inc. and has been active in neuropharmacology for more than 35 years, holding positions at Yale University, the National Institute of Mental Health, The Salk Institute, and The Scripps Research Institute. From 1983 to February 2005, Dr. Bloom was the Chairman of the Neuropharmacology Department at The Scripps Research Institute and is now Professor Emeritus. Dr. Bloom served as Editor-in-Chief of Science from 1995 to May 2000. He is a member of the National Academy of Sciences, the Royal Swedish Academy of Science and the American Philosophical Society. He is an Emeritus Trustee for the Board of Trustees at Washington University in St. Louis. Dr. Bloom is a director of AgeneBio, Inc. a privately held biopharmaceutical company. Dr. Bloom also serves on the Scientific Advisory Boards of aTyr Pharma, a privately held pharmaceutical company, RiverVest, a private venture partnership focusing on life sciences, and Interpreta Inc., a privately held analytics service company, and as chairman of the Scientific Board for ModGene Pharma LLC, a privately held research and development company. Dr. Bloom served as a member of the board of directors of Elan from 2007 to 2009.

Basic Compensation

Total Annual Compensation, USD 89,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 373,051
Fiscal Year Total, USD 462,051

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Pops


James Frates


Elliot Ehrich


Iain Brown


David Gaffin


Michael Landine

As Of  31 Dec 2017